Table 1.
Baseline characteristics of the study groups (intention-to-treat analysis)
| CDCM | Placebo | |
|---|---|---|
| Gender, n/N (%) | ||
| Male | 41/88 (46.59%) | 39/88 (44.32%) |
| Female | 47/88 (53.41%) | 49/88 (55.68%) |
| Age (years) | n = 88 | n = 88 |
| Mean ± SD | 42.06 ± 14.97 | 44.08 ± 16.16 |
| Median; range (IQR) | 41.5; 18–76 (30–52) | 42; 18–77 (30–56) |
| No co-morbidity, n/N (%) | 65/82 (79.27%) | 65/85 (76.47%) |
| Diagnosis to inclusion time (days) | n = 87 | n = 83 |
| Mean ± SD | 3.71 ± 4.11 | 2.84 ± 1.57 |
| Median; range (IQR) | 4; 0–38 (2–4.5) | 3; 0–8 (2–4) |
| Initial place of care, n/N (%) | ||
| Home | 80/85 (94.12%) | 77/84 (91.67%) |
| Hospital | 5/85 (5.88%) | 6/84 (7.14%) |
| Nursing care | 0/85 (0.00%) | 1/84 (1.19%) |
| Diagnostic delay to day 1 (days) | n = 87 | n = 84 |
| Mean ± SD | 4.3 ± 3.34 | 3.61 ± 1.48 |
| Median; range (IQR) | 4; 0–31 (3–5) | 4; 1–8 (3–5) |
| Delay clinical signs to day 1 (days) | n = 76 | n = 82 |
| Mean ± SD | 5.59 ± 1.54 | 5.46 ± 1.67 |
| Median; range (IQR) | 6; 2–9 (4.75–7) | 6; 1–9 (4.25–7) |
| Delay PCR to day 1 (days) | n = 85 | n = 84 |
| Mean ± SD | 4.11 ± 1.53 | 3.73 ± 1.45 |
| Median; range (IQR) | 4; 1–8 (3–5) | 4; 0–8 (3–5) |
Abbreviations: CDCM, β-cyclodextrin-citrox mouthwash; IQR, interquartile range; SD, standard deviation.